| Hazard ratio | 95% CI for HR | Total P-value |
---|---|---|---|
Univariate analysis | |||
 Base model | |||
 FIGO stage | |||
 III-IV vs I-II | 5.98 | 3.11–9.89 | < 0.001 |
 Age (years) | |||
 > 60 vs ≤60 | 2.31 | 1.24–4.58 | 0.013 |
 Grade | |||
 1 vs 2 | 2.59 | 1.16–4.86 | 0.062 |
 Myometrial invasion | |||
 > 50% vs ≤50% | 3.28 | 1.83–5.92 | < 0.001 |
 LVSI | |||
 yes vs no | 2.63 | 1.24–4.76 | 0.009 |
 Additions to modela | |||
 VEGF-A | 1.02 | 0.25–3.64 | 0.74 |
 Ang-2 | 1.29 | 1.09–1.59 | < 0.001 |
 Adiponectin | 1.01 | 0.99–1.06 | 0.923 |
 Insulin | 1.00 | 0.98–1.02 | 0.914 |
 C-peptide | 1.02 | 0.97–1.06 | 0.689 |
 CRP | 1.37 | 1.03–1.61 | < 0.001 |
 IGF-1 | 1.01 | 0.96–1.05 | 0.893 |
 BMI | 0.84 | 0.45–1.41 | 0.472 |
Multivariate analysis | |||
 Base model | |||
 FIGO stage | |||
 III-IV vs I-II | 3.57 | 1.79–6.94 | < 0.001 |
 Age (years) | |||
 > 60 vs ≤60 | 2.21 | 1.19–4.32 | 0.017 |
 Grade | |||
 1 vs 2 | 1.52 | 1.18–2.96 | 0.683 |
 Myometrial invasion | |||
 > 50% vs ≤50% | 1.11 | 0.49–2.09 | 0.861 |
 LVSI | |||
 yes vs no | 1.16 | 0.53–2.36 | 0.734 |
Additions to modelb | |||
 Ang-2 | 1.31 | 1.02–1.69 | 0.006 |
 CRP | 1.22 | 1.01–1.43 | 0.015 |